Gerlach H, Pappert D, Lewandowski K, Rossaint R, Falke K J
Clinic for Anesthesiology and Intensive Care Medicine, University Clinic Rudolf Virchow, Free University of Berlin, Germany.
Intensive Care Med. 1993;19(8):443-9. doi: 10.1007/BF01711084.
To evaluate the lowest dose of inhaled nitric oxide (NO) in patients with adult respiratory distress syndrome (ARDS), which is able to improve arterial oxygenation more than 30% compared to baseline data.
Prospective, clinical study.
Anesthesiological ICU in a university hospital.
3 consecutive patients with severe ARDS according to clinical and radiological signs.
Pressure-controlled ventilation with positive end-expiratory pressure of 8-12 cm H2O. Inhalation of NO was performed with a blender system and a Servo 300 ventilator. The lowest effective NO dose was defined by titrating the inspiratory NO dose until reaching a 30% improvement of PaO2/FiO2. This dose was used for the following continuous long-term NO inhalation; controls of efficacy by investigation of hemodynamics and blood gas exchange were performed initially and 2 times per patient after intervals of 3-5 days.
Initial NO concentrations were found to be effective at 60, 100, and 230 parts per billion (ppb). In all measurements, arterial oxygenation was found to be elevated by NO inhalation with the initially evaluated dose compared to baseline data; in parallel, the venous admixture (Qva/Qt) was reduced. The O2 delivery increased, although O2 consumption and hemodynamics did not change. In 1 patient, interruption of NO inhalation caused remarkable increase of pulmonary resistance.
The improvement of oxygenation by NO inhalation in ARDS does not require reduction of pulmonary resistance and can be performed using low doses in the ppb range, which has to be considered as probably non-toxic.
评估吸入一氧化氮(NO)治疗成人呼吸窘迫综合征(ARDS)患者时,相较于基线数据能使动脉氧合改善超过30%的最低剂量。
前瞻性临床研究。
大学医院的麻醉重症监护病房。
根据临床和放射学体征选取3例连续的重度ARDS患者。
采用呼气末正压8 - 12 cm H₂O的压力控制通气。使用混合器系统和Servo 300呼吸机进行NO吸入。通过滴定吸入NO剂量直至达到PaO₂/FiO₂改善30%来确定最低有效NO剂量。该剂量用于后续持续长期的NO吸入;最初以及每位患者每隔3 - 5天进行2次,通过血流动力学和血气交换检查来控制疗效。
初始NO浓度在60、100和230十亿分率(ppb)时有效。在所有测量中,与基线数据相比,吸入最初评估剂量的NO可使动脉氧合升高;同时,静脉血掺杂(Qva/Qt)降低。尽管氧耗量和血流动力学未改变,但氧输送增加。1例患者中断NO吸入导致肺阻力显著增加。
ARDS患者吸入NO改善氧合并不需要降低肺阻力,且可使用ppb范围内的低剂量,这可能被认为是无毒的。